Nasdaq · Healthcare
BIOCRYST PHARMACEUTICALS INC (BCRX)
As-reported financials and recent SEC filings for BIOCRYST PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$874.8M
Net income
$263.9M
Net margin
30.2%
Diluted EPS
$1.21
ROE
-221.4%
P/E (TTM)
8.2×
Market cap
$2.53B
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $341.0M | $-2.5M | $-103.7M | $-148.4M | $-177.7M |
| Net income | $263.9M | $-88.9M | $-226.5M | $-247.1M | $-184.1M |
| Diluted EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on BCRX
Search BIOCRYST PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.